Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN versus CLARITIN D 24 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN versus CLARITIN D 24 HOUR.
CLARITIN vs CLARITIN-D 24 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity. It inhibits histamine release from mast cells and reduces allergic responses.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism; pseudoephedrine is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa.
10 mg orally once daily for adults and children ≥6 years.
1 tablet (10 mg loratadine/240 mg pseudoephedrine) orally once daily
None Documented
None Documented
Terminal elimination half-life 27 hours (range 22-30 hours); clinical context: allows once-daily dosing, steady state reached in 5-7 days
Loratadine: 8-11 hours (mean 10.6 ± 4.6 h); desloratadine: 17-24 hours (mean 19.4 ± 7.5 h). Terminal half-life is prolonged in chronic hepatic impairment (mean 37 h for loratadine, 47 h for desloratadine).
Renal 40% as metabolites, fecal 40% as metabolites, biliary <5% as unchanged drug
Renal (40%) as unchanged drug and metabolites; biliary/fecal (minor). Approximately 27% of loratadine and 40% of desloratadine are excreted in urine over 10 days.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination